CHA
FLGT icon

Carmichael Hill & Associates’s Fulgent Genetics FLGT Stock Holding History

Carmichael Hill & Associates’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-500
Closed -$32.9K – 809
2021
Q4 		$50K Hold
500
– – 0.02% 366
2021
Q3 		$45K Hold
500
– – 0.02% 368
2021
Q2 		$46K Buy
500
+100
+25% +$7.98K 0.02% 367
2021
Q1 		$39K Buy
+400
New +$41.3K 0.02% 378

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Carmichael Hill & Associates's FLGT Position: Q1 2022 in Review

Carmichael Hill & Associates sold out of Fulgent Genetics (FLGT) in Q1 2022, closing a stake of 500 shares — an estimated $32.9K sold.

Carmichael Hill & Associates first reported a position in FLGT in Q1 2021 and held it in 4 quarters. The position peaked at $50K in Q4 2021. 275 funds tracked by Wall St. Rank hold FLGT as of Q1 2022.

  • Carmichael Hill & Associates reported no remaining Fulgent Genetics position as of Q1 2022 after selling out during the quarter.
  • Carmichael Hill & Associates sold 500 Fulgent Genetics shares in Q1 2022, an estimated $32.9K.
  • Carmichael Hill & Associates first reported a position in Fulgent Genetics in Q1 2021 and held it in 4 quarters.
  • Carmichael Hill & Associates's Fulgent Genetics position peaked at $50K in Q4 2021.
  • 275 funds tracked by Wall St. Rank held Fulgent Genetics as of Q1 2022.

Based on Carmichael Hill & Associates's 13F filing for Q1 2022, filed 16 May 2022.